Olumuyiwa Idowu, MD
Internal Medicine · Chicago, ILNPI 1538254511
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,499 of the $3,644 with a category attached, or 68.6%. 23 manufacturers reported payments, led by Globus Medical at 45.5% of the total. Reporting peaked in 2024 at $1,711 and has fallen 58.0% since, to $719 in 2025. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 97 payments — averaging $37.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Globus Medical$2K
- Lilly USA, LLC$441
- Sunovion Pharmaceuticals Inc.$241
- Organogenesis Inc.$132
- AstraZeneca$123
- Saxum Surgical, Inc.$122
- plus $926 from 17 others
Across 29 payments — averaging $4311.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exact Sciences$125K
What the payments were for
- Travel & lodging$1,14431%
- Food & beverage$2,49969%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Globus Medical(2 entities) | 11 | $1,659 |
| Lilly USA, LLC | 19 | $441 |
| Sunovion Pharmaceuticals Inc. | 14 | $241 |
| Organogenesis Inc. | 6 | $132 |
| AstraZeneca | 5 | $123 |
| Saxum Surgical, Inc. | 1 | $122 |
| Novo Nordisk | 6 | $107 |
| Pfizer | 4 | $103 |
| UCB, Inc. | 4 | $92 |
| Sumitomo Pharma America, Inc. | 4 | $87 |
| Teva Pharmaceuticals USA, Inc. | 3 | $84 |
| SK Life Science, Inc. | 3 | $78 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| Gilead | 2 | $40 |
| Philips North America LLC | 1 | $36 |
| Medtronic | 1 | $34 |
| Lundbeck LLC | 2 | $31 |
| Boehringer Ingelheim | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Novartis | 1 | $23 |
| Amgen | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Captivate VL$1,144
- ALTERA$190
- ACP$151
How this compares
$3,644 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 164 | $87,042 |
| AptiomEslicarbazepine Acetate | 130 | $83,059 |
| EliquisApixaban | 248 | $81,532 |
| TrulicityDulaglutide | 83 | $71,938 |
| AustedoDeutetrabenazine | 27 | $64,996 |
| OzempicSemaglutide | 41 | $62,514 |
| FanaptIloperidone | 28 | $48,591 |
| Breo ElliptaFluticasone/Vilanterol | 72 | $32,111 |
| JanuviaSitagliptin Phosphate | 60 | $30,450 |
| NamzaricMemantine Hcl/Donepezil Hcl | 83 | $16,726 |
| FarxigaDapagliflozin Propanediol | 16 | $14,684 |
| XareltoRivaroxaban | 23 | $13,396 |
| LinzessLinaclotide | 13 | $12,659 |
| GemtesaVibegron | 40 | $10,791 |
| Atorvastatin Calcium | 763 | $10,174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $27 | $87,042164 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $241 | $83,059130 claims |
| PfizerEliquis | $103 | $81,532248 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $441 | $75,006181 claims |
| Novo NordiskOzempic, Levemir, Novolog | $107 | $69,124105 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $84 | $64,99627 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $25 | $48,59128 claims |
| AstraZenecaFarxiga | $123 | $14,68416 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $87 | $10,79140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Chicago
- Merle DiamondChicago$1.1M
- Robert KushnerChicago$516K
- Romeo UrsuaChicago$420K
- Peter O DonnellChicago$318K
- George UrbanChicago$258K
- Kristen PallokChicago$256K
- George NissanChicago$252K
- Luke LaffinChicago$162K
- Daniel CatenacciChicago$161K
- Hiren ShahChicago$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.